SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001176256-15-000122
Filing Date
2015-03-31
Accepted
2015-03-31 15:47:35
Documents
9
Period of Report
2014-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 nymoxpharma20f141231.htm 20-F 1198534
2 6% SECURED CONVERTIBLE NOTE DATED DECEMBER 16, 2014 exhibit4-x.htm EX-4.X 54488
3 SOX SECTION 302 CEO CERTIFICATION exhibit12-a.htm EX-12.A 5477
4 SOX SECTION 302 CFO CERTIFICATION exhibit12-b.htm EX-12.B 5460
5 SOX SECTION 906 CEO CERTIFICATION exhibit13-a.htm EX-13.A 1644
6 SOX SECTION 906 CFO CERTIFICATION exhibit13-b.htm EX-13.B 1616
7 nymoxpharma20fp2x1x1.jpg GRAPHIC 7324
8 nymoxpharma20fp2x2x1.jpg GRAPHIC 3801
9 nymoxpharma20fp2x2x2.jpg GRAPHIC 6677
  Complete submission text file 0001176256-15-000122.txt   1293219
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 15739002
SIC: 2835 In Vitro & In Vivo Diagnostic Substances